½ÃÀ庸°í¼­
»óǰÄÚµå
1741545

¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°

Global Plasma Protein Therapeutic Market, By Product Type, By Application, By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀåÀº 2025³â¿¡´Â 339¾ï 9,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â±îÁö´Â 528¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â ½ÃÀå ±Ô¸ð(2025³â) 339¾ï 9,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ CAGR(2025-2032³â) : 6.50% ¿¹Ãø ±Ý¾×(2032³â) 528¾ï 2,000¸¸ ´Þ·¯

Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦¶õ Àΰ£ÀÇ Ç÷Àå¿¡¼­ À¯·¡ÇÏ´Â Ä¡·á¿ë Á¦Ç°À» °¡¸®Å°¸ç, ¸¸¼º Áúȯ µî ´Ù¾çÇÑ º´¸®ÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. Ç÷Àå¿¡´Â 700°¡Áö ÀÌ»óÀÇ ´Ü¹éÁúÀÌ µé¾î ÀÖ°í ü³»¿¡¼­ ¿©·¯ °¡Áö Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦·Î´Â ¸é¿ª±Û·ÎºÒ¸°, ÀÀ°í ÀÎÀÚ, ¾ËºÎ¹Î, ±âŸ Ư¼ö ´Ü¹éÁú µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷Àå À¯·¡ Á¦Ç°Àº ¸é¿ª ü°èÀÇ °­È­, Ç÷¾× ÀÀ°í, ±âŸ ´ë»ç °úÁ¤¿¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀ» ¾Î´Â ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ç÷Àå Ä¡·áÁ¦ÀÇ ¼ö¿ä´Â Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °íµµÀÇ Á¤Á¦ ±â¼ú·Î Ç÷Àå¿¡¼­ Áß¿äÇÑ ´Ü¹éÁúÀ» ºñ¿ë È¿À²ÀÌ ³ôÀº ¹æ¹ýÀ¸·Î ´ëÆø ȸ¼öÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀåÀº Ç÷Àå º¸Ãæ ¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â ¸é¿ª °áÇÌ ÁúȯÀ̳ª À¯Àü¼º ÁúȯÀÇ À¯º´·üÀÇ »ó½Â¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ÃâÇ÷¼º Áúȯ°ú °°Àº ¸¸¼º Áúȯ¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡µµ ¼ö¿ä¸¦ ÁöÁöÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Ç÷Àå À¯·¡ Á¦Ç°À» °³¹ßÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ³ë·Â ¹× ÀǷẸÇè Á¦µµÀÇ Àû¿ë¹üÀ§ È®´ë°¡ ÀÌ ºÐ¾ß¿¡ ºñÁî´Ï½º ±âȸ¸¦ °¡Á®´Ù ÁÖ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Ç÷Àå äÃë¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í Ç÷ÀåºÐȹ Ç÷£Æ®¿¡ ÇÊ¿äÇÑ °í¾× ÀÚº»ÀÌ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ëü À¯ÀüÀÚ ÀçÁ¶ÇÕ ¿ä¹ýÀÇ ÃâÇöµµ ½ÃÀåÀÇ ¼ºÀåÀ» À§ÇùÇϰí ÀÖ½À´Ï´Ù. ÀûÀýÇÑ ½ºÅ©¸®´×ÀÌ ÀÌ·ç¾îÁöÁö ¾ÊÀ» °æ¿ìÀÇ Ç÷ÀåÁ¶´Þ¿¡ °üÇÑ ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Áµµ ½ÃÀå ¼ºÀå¿¡ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2023³â 6¿ù 26ÀÏ, National Center for Biotechnology InformationÀÌ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2021³â Çѱ¹¿¡¼­ÀÇ ¿ø¹ß¼º ¸é¿ª °áÇÌÁõ(PID)ÀÇ ¹ß»ý·üÀº ¼Ò¾Æ 100¸¸ ¸í´ç ¾à 11.25¸íÀ̾ú½À´Ï´Ù. °¡Àå ¸¹ÀÌ È®ÀÎµÈ ¸é¿ª°áÇÌÁõÀº Ç×ü¿¡ °üÇÑ °ÍÀ¸·Î 53.3%¸¦ Â÷ÁöÇß°í, ޽O÷ Àå¾Ö°¡ 28.9%·Î µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶Ç, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ¼ºÀå ±âȸ¸¦ ¹àÇô, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ¼­ ÇØ¼³Çß½À´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±Ù°ÅÇØ, ¼¼°è Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× ±â¾÷ °æ¿µÁøÀÌ, Àå·¡ÀÇ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç °áÁ¤À» ½Ç½ÃÇÏ´Â °ÍÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
  • ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû ¹× ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ÀϰüµÈ ±âȸ Áöµµ(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ¼­ºñ½º Á¦°ø Æ÷Æ®Æú¸®¿À
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´ ¹× Àμö ½Ã³ª¸®¿À

Á¦4Àå ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå : Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±ÞÃø ¹× ¼ö¿äÃø ºÐ¼®
  • °æÁ¦¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå : Á¦Ç° À¯Çüº°(2020-2032³â)

  • ¾ËºÎ¹Î
  • ¸é¿ª±Û·ÎºÒ¸°
  • Ç÷Àå À¯·¡ ÀÎÀÚ VIII
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°(2020-2032³â)

  • Ç÷¿ìº´
  • ¿ø¹ß¼º ¸é¿ª °áÇÌÁõ(PIDD)
  • Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º Àڹݺ´(ITP)
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2020-2032³â)

  • º´¿ø
  • Ŭ¸®´Ð
  • ¿¬±¸½Ç
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ Ç÷Àå ´Ü¹éÁú Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°(2020-2032³â)

  • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
  • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ½ºÆäÀÎ
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ·¯½Ã¾Æ
      • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • Àεµ
      • ÀϺ»
      • È£ÁÖ
      • Çѱ¹
      • ASEAN
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
      • GCC ±¹°¡
      • À̽º¶ó¿¤
      • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
      • ºÏ¾ÆÇÁ¸®Ä«
      • Áß¾Ó ¾ÆÇÁ¸®Ä«
      • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Octapharma USA Inc.
  • Biotest AG
  • Kedrion SpA
  • CSL Limited
  • Grifols, SA
  • Takeda Pharmaceutical Company Limited.
  • Octapharma AG
  • Bio Products Laboratory(BPL)
  • Shire Plc
  • Albumedix Ltd.

Á¦10Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
AJY

Global Plasma Protein Therapeutic Market is estimated to be valued at USD 33.99 Bn in 2025 and is expected to reach USD 52.82 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 33.99 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.50% 2032 Value Projection: USD 52.82 Bn

Plasma protein therapeutic refers to therapeutic products that are derived from human blood plasma and are used for treating various medical conditions such as chronic disease and others. Blood plasma contains over 700 different proteins and serves various important functions in the body. Some of the major plasma protein therapeutics include immunoglobulins, coagulation factors, albumin, and other specialty proteins. These plasma derived products help in boosting the immune system, blood clotting, and other metabolic processes. With the growing geriatric population suffering from chronic diseases, there has been a rise in the demand for plasma therapeutics globally. Also, advanced purification technology has enabled significant yield of critical proteins from plasma in a cost-effective manner.

Market Dynamics:

The global plasma protein therapeutic market is driven by the rising prevalence of immune deficiency diseases and genetic disorders requiring plasma replacement therapies. The growing geriatric population prone to chronic illnesses like bleeding disorders is also supporting the demand. Continuous R&D efforts to develop new plasma-derived products and wider coverage under medical insurance schemes are providing opportunities in this space. However, stringent regulations pertaining to plasma collection and high capital requirements for plasma fractionation plants act as challenges. Also, the emergence of alternative recombinant therapies threatens the market growth. Safety concerns around plasma sourcing if not properly screened also hinder the market growth.

For instance, on June 26, 2023, according to a report published by the National Center for Biotechnology Information, in 2021, in South Korea, the occurrence rate of primary immunodeficiencies (PID) stood at around 11.25 cases per million children. The most commonly identified immunodeficiencies were those related to antibodies, constituting 53.3%, with phagocytic disorders trailing at 28.9%.

Key features of the study:

  • This report provides an in-depth analysis of the global plasma protein therapeutic market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global plasma protein therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Octapharma USA Inc., Biotest AG, Kedrion S.p.A, CSL Limited, Grifols, S.A, Takeda Pharmaceutical Company Limited., Octapharma AG, Bio Products Laboratory (BPL), Shire Plc, and Albumedix Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global plasma protein therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protein therapeutic market

Global Plasma Protein Therapeutic Market Detailed Segmentation:

  • By Product Type
    • Albumin
    • Immunoglobulin
    • Plasma-derived Factor VIII
    • Others
  • By Application
    • Haemophilia
    • Primary Immunodeficiency Disorder (PIDD)
    • Idiopathic Thrombocytopenic Purpura (ITP)
    • Others
  • By End User
    • Hospitals
    • Clinics
    • Research Laboratories
    • Others
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Octapharma USA Inc.
    • Biotest AG
    • Kedrion S.p.A
    • CSL Limited
    • Grifols, S.A
    • Takeda Pharmaceutical Company Limited.
    • Octapharma AG
    • Bio Products Laboratory (BPL)
    • Shire Plc
    • Albumedix Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Plasma Protein Therapeutic Market, By Product Type
    • Global Plasma Protein Therapeutic Market, By Application
    • Global Plasma Protein Therapeutic Market, By End User
    • Global Plasma Protein Therapeutic Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Prevalence of Complement Deficiency Diseases
    • High R&D and Production Costs
    • Immune Globulin for Various Disease Treatment
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Service offering Portfolio
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Plasma Protein Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Plasma Protein Therapeutic Market, By Product Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Albumin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Immunoglobulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Plasma-derived Factor VIII
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Plasma Protein Therapeutic Market, By Application, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Haemophilia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Primary Immunodeficiency Disorder (PIDD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Idiopathic Thrombocytopenic Purpura (ITP)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Plasma Protein Therapeutic Market, By End User, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Research Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Plasma Protein Therapeutic Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Octapharma USA Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Biotest AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Kedrion S.p.A
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • CSL Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Grifols, S.A
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Octapharma AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Bio Products Laboratory (BPL)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Shire Plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Albumedix Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

10. Section

  • Research Methodology
  • About us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦